Yes there is a lot of low hanging fruit in repurposing existing drugs for new indications. The difficulty can be that many of these newly discovered drugs hit a very limited subset of cancer sub-types. This can make it really hard to make a commercial drug out of these discoveries as the market can be tiny. Having a drug like Bisantrene that works on a wide variety of cancers is really, really useful when you are trying to get a large Pharma company to financially support the Phase III trials needed to bring a drug to market.
I have to sit down and read the original paper in depth. Here is the link for those interested.
https://www.nature.com/articles/s43018-019-0018-6
-
- There are more pages in this discussion • 9,547 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
-0.040(3.23%) |
Mkt cap ! $208.4M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.24 | $1.20 | $103.7K | 85.92K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 12091 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 9720 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |